Diasorin is committed to identifying customer needs and to developing and bringing to market in vitro diagnostic products that meet legislative requirements and optimize the clinical utility of the analytical information.

The mission of Diasorin is, in fact, to contribute to the improvement of health care by bringing to market diagnostic tests that can orient better medical decisions, while curbing public health care costs.

To accomplish this, Diasorin has identified the fundamental components of its strategy in which the company will continue to invest:

Innovation and technological excellence, at the level of both reagents and assay architecture, for which a targeted personnel policy is pursued to have professionals able to effectively operate at international level in the research and development of new technologies, products and processes, thus promoting the creation and exchange of know-how.

An active relationship with the customer, seen as a partner rather than as a mere product user, who will share in the search for continuing improvement.

An active cooperation with suppliers to be involved in the company project, within a relationship of mutual trust and transparency.

A continued strengthening of a culture for quality as a way of thinking and behaving in the company and as a competitive advantage on the market.

Furthermore, Diasorin is committed to the observance of all applicable legislation and to laws concerning the safety of operators, users and the environment.